HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on AEON Biopharma but lowered the price target from $6 to $5.
August 14, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on AEON Biopharma but lowered the price target from $6 to $5.
The maintained Buy rating suggests continued confidence in AEON Biopharma's prospects, but the lowered price target indicates some caution regarding its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100